Answer
Because excretion of dabrafenib mesilate into human milk is unknown and risk to the breastfed child cannot be excluded, a decision is needed whether to discontinue breastfeeding or dabrafenib, weighing breastfeeding's benefit for the child against treatment's benefit for the woman.
Sources for this answer
- Tafinlar 50 mg & 75 mg hard capsulesNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 40Document updated
Sources checked